iShares Genomics Immunology and Healthcare ETF
IDNA
60 hedge funds and large institutions have $61.8M invested in iShares Genomics Immunology and Healthcare ETF in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
12% more capital invested
Capital invested by funds: $55M → $61.8M (+$6.8M)
3% more funds holding
Funds holding: 58 → 60 (+2)
0.81% less ownership
Funds ownership: 41.71% → 40.91% (-0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.25M |
| 2 |
Morgan Stanley
New York
|
+$920K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$685K |
| 4 |
GS
GTS Securities
New York
|
+$676K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$408K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$1.85M |
| 2 |
Jane Street
New York
|
-$1.37M |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$1.08M |
| 4 |
OC
Opal Capital
Boca Raton,
Florida
|
-$604K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$331K |
IDNA Hedge Fund Activity: Q1 2026 in Review
60 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q1 2026, worth a combined $61.8M — up 12% from $55M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IDNA positions and 6 closed out — a net gain of 3 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was Bank of America, adding an estimated $3.25M. The largest seller was Raymond James Financial, cutting an estimated $1.85M.
- 60 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q1 2026, up from 58 in Q4 2025.
- Funds reported $61.8M of iShares Genomics Immunology and Healthcare ETF stock for Q1 2026, up 12% quarter-over-quarter.
- 9 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q1 2026 and 6 closed out, a net change of +3 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q1 2026 was Bank of America, an estimated $3.25M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q1 2026 was Raymond James Financial, an estimated $1.85M sold.
Based on aggregated 13F filings for Q1 2026.